Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ambrx Biopharma Inc

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today it has entered into a definitive agreement to acquire Ambrx Biopharma, Inc., or Ambrx (NASDAQ: AMAM), a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash merger transaction for a total equity value of approximately $2.0 billion, or $1.9 billion net of estimated cash acquired.

Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer

Johnson & Johnson's leading product, Stelara, is nearing the end of its exclusivity, which will likely slow down the growth of earnings per share. JNJ prioritizes growth in investments, with a focus on pharmaceuticals, medtech, and potential inorganic growth. JNJ anticipates launching new therapies and targeting key areas in the pharmaceutical and medtech sectors to drive growth.

Johnson & Johnson: Overblown Stelara Concerns Distract From Value

Amgen

Cisco Systems

Chevron

Dow Inc

Coca-Cola

Verizon

Walgreens

The 2024 Dogs of the Dow are particularly homely hounds—which means we're talking big dividends.

Dogs Of The Dow 2024: 10 Blue-Chip Dividend Payers

AbbVie

Ares Capital

Broadcom

Bank of America

Brookfield Renewable Partners

Brookfield Infrastructure Partners L.P.

Brookfield Infrastructure

Conagra Brands

Crown Castle International

CVS Health

Devon Energy

Enbridge

Enterprise Products Partners

Energy Transfer LP Unit

Goldman Sachs

Hormel Foods

Lowe's

Pfizer

Public Storage

Rithm Capital Corp

Target

T-Mobile US

Stocks from multiple sectors, including consumer goods, energy, and healthcare, made the list. Their dividend yields range from a low of 2% to a high of 9.7%.

24 Top Dividend Stocks to Buy and Hold in 2024

Microsoft

The Dow Jones Industrial Average is up 3.64% over the past month, and technical indicators show that it could extend much further. If last year's repeat of the ‘Majestic Seven' leading the broader indices again happens this year, we could be in for a bit of a wild ride.

Dow Darlings: Top 3 Stocks That Will Lead the Charge in 2024

Bristol-Myers

MPLX

NextEra Energy

PepsiCo

Visa

This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering large discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks. In addition to the primary list that yields just over 3%, we present two other groups of five DGI stocks each, with the goal of moderate to high yields.

5 Relatively Secure And Cheap Dividend Stocks To Invest In - January 2024

Johnson & Johnson is a Dividend King focused on the creation and manufacturing of medical devices, vaccines, and medicines. Sales of Darzalex, an anti-CD38 monoclonal antibody, were $2.5 billion in the third quarter of 2023, up 21.8% year-over-year. In the short term, I expect a technical pullback of the company's share price to $155, due to the bearish RSI divergence.

Johnson & Johnson's Bullish Outlook: Surprising Strength You Shouldn't Overlook

Bayer AG

Banco de Chile

British American Tobacco

ING Groep NV

JPMorgan Chase & Co

Altria

Realty Income Corp

AT&T

Zurich Insurance Group AG

High dividend yield companies are essential components within a well-balanced and diversified dividend portfolio, particularly for those seeking to generate substantial additional income via dividends. In this article, I will present 10 high dividend yield companies that are worth considering an investment in due to their attractive Valuation, high Dividend Yield, and financial health. 3 of the 10 selected picks provide investors with a Dividend Yield [FWD] above 9%: Altria (9.76%), British American Tobacco (9.55%) and Banco de Chile (9.40%).

Up To 10% Yields: My Top 10 High Dividend Yield Companies For January 2024

Johnson & Johnson is a safe and stable business with an AAA rating and a 60+ year history of dividend increases. JNJ has a strong balance sheet, generating significant free cash flow and having the resources for investments and shareholder rewards. The stock trades at an attractive valuation with potential for dividend growth and EPS growth.

Johnson & Johnson: A Defensive Dividend King Set To Outperform The S&P 500

The Fed's potential rate cuts are causing concern in the market, as it could lead to higher inflation and negatively impact stocks. Johnson & Johnson (JNJ) is a safe investment option with a history of consistent income and extreme financial safety. JNJ's recent performance, positive business developments, and long-term growth prospects make it a compelling investment for conservative investors.

Johnson & Johnson - One Of The World's Safest Stocks Could Return +10% Per Year

Johnson & Johnson's stock has underperformed the market, but its strong performance and secure balance sheet make it an attractive investment during uncertainty. The company's Q3 results showed solid growth, and it raised its full-year outlook, projecting a 13% year-over-year growth in EPS. JNJ offers a solid 3% dividend yield backed by a 61-year track record. Its AAA balance sheet rating and 46% payout ratio ensure strong safety and reliability.

Johnson & Johnson: Rock Solid 3% Yield With Over 10% Return Potential (Rating Upgrade)

Boeing

Salesforce

Disney

Intel

McDonald's

NIKE

Procter & Gamble

Walmart

"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation.is also a consideration.” – Dow Jones & Co. The highest-yield 10 stocks are December's Dogs of the Dow: JNJ, AMGN, KO, CSCO, CVX, IBM, DOW, MMM, VZ, and WBA. They only averaged a 4.49% annual yield, as prices. Thirty Dow stocks represent nine of eleven sectors. Dow Jones tracks utilities as a separate index and omits real estate. Broker top-ten target-estimated December net gains ranged 10.25%-22.59%, topped by CVX 1/2/24.

January Dogs Of The Dow: 2 Buyable, 6 Watchable

Duke Energy

It's a new year and apparently there's a new theme on Wall Street for investors. Many of the Magnificent Seven stocks and their high-flying tech peers are off to a difficult start in 2024.

Revenge of the Boring Stocks! Dividends Are Sexy Again.

News for Johnson & Johnson Stock (JNJ)